| Pharmaceutical Information |
| Drug Name |
Omalizumab |
| Drug ID |
BADD_D01610 |
| Description |
Omalizumab, manufactured by _Genentech_, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids [L4670]. Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated [L4670]. In September 2018, a new prefilled syringe formulation of this drug was approved by the FDA [L4671]. |
| Indications and Usage |
For treatment of asthma caused by allergies |
| Marketing Status |
Prescription |
| ATC Code |
R03DX05 |
| DrugBank ID |
DB00043
|
| KEGG ID |
D05251
|
| MeSH ID |
D000069444
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D02GEC
|
| NDC Product Code |
50242-214; 50242-215; 50242-040 |
| Synonyms |
Omalizumab | Xolair |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
242138-07-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
